August 26, 2021 – The Sickle Cell Disease Association of America Medical and Research Advisory Committee has released a statement with updated COVID-19 guidance.
MARAC recommends that people with sickle cell disease should have access to monoclonal antibody (mAbs) treatment according to established guidelines, to prevent mild COVID from progressing to severe disease.
Read the full recommendations for providers, policy makers and patients.
Original published date
Original source URL
Original source title
sicklecelldisease.org
Original updated date